In mice with low Fh1 expression, the efficacy of PD-1 antibodies was enhanced when the treatment was combined with a PCSK9 inhibitor. CRC patients with low FH expression might experience improved outcomes from a combined therapy of PD-1 antibodies and PCSK9 inhibitors. This evidence concerns the gene PDCD1 and colorectal carcinoma.